# Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy

> **NCT05180006** · PHASE2 · TERMINATED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 33 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Atezolizumab Injection
- **DRUG:** Bevacizumab
- **DRUG:** Pertuzumab
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT05180006
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-24
- **Primary completion:** 2024-12-17
- **Final completion:** 2024-12-17
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** Abandon of the partner, ROCHE
- **Last updated:** 2025-12-01

## Collaborators

- Hoffmann-La Roche

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05180006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05180006, "Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy". Retrieved via AI Analytics 2026-08-10 from https://api.ai-analytics.org/clinical/NCT05180006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*